SG11202112435WA - Methods for treating chronic obstructive pulmonary disease in an enhanced patient population using benralizumab - Google Patents

Methods for treating chronic obstructive pulmonary disease in an enhanced patient population using benralizumab

Info

Publication number
SG11202112435WA
SG11202112435WA SG11202112435WA SG11202112435WA SG11202112435WA SG 11202112435W A SG11202112435W A SG 11202112435WA SG 11202112435W A SG11202112435W A SG 11202112435WA SG 11202112435W A SG11202112435W A SG 11202112435WA SG 11202112435W A SG11202112435W A SG 11202112435WA
Authority
SG
Singapore
Prior art keywords
benralizumab
methods
pulmonary disease
chronic obstructive
obstructive pulmonary
Prior art date
Application number
SG11202112435WA
Inventor
Ubaldo Martin
Maria Jison
Paul Newbold
Peter Barker
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SG11202112435WA publication Critical patent/SG11202112435WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202112435WA 2019-05-16 2020-05-15 Methods for treating chronic obstructive pulmonary disease in an enhanced patient population using benralizumab SG11202112435WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962848875P 2019-05-16 2019-05-16
PCT/IB2020/054618 WO2020230097A1 (en) 2019-05-16 2020-05-15 Methods for treating chronic obstructive pulmonary disease in an enhanced patient population using benralizumab

Publications (1)

Publication Number Publication Date
SG11202112435WA true SG11202112435WA (en) 2021-12-30

Family

ID=70779821

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202112435WA SG11202112435WA (en) 2019-05-16 2020-05-15 Methods for treating chronic obstructive pulmonary disease in an enhanced patient population using benralizumab

Country Status (11)

Country Link
US (1) US20200362027A1 (en)
EP (1) EP3969048A1 (en)
JP (1) JP2022532220A (en)
KR (1) KR20220009967A (en)
CN (1) CN114007641A (en)
AU (1) AU2020273681A1 (en)
CA (1) CA3138997A1 (en)
IL (1) IL287998A (en)
SG (1) SG11202112435WA (en)
TW (1) TW202110479A (en)
WO (1) WO2020230097A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2233974T3 (en) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. ANTIBODY AGAINST THE ALFA CHAIN OF THE 5 HUMAN INTERLEUCINE RECEIVER.
MX2020011303A (en) 2007-05-14 2021-12-17 Astrazeneca Ab Methods of reducing eosinophil levels.
TR201907907T4 (en) * 2013-08-12 2019-06-21 Astrazeneca Ab Methods of increasing the forced expiratory volume in asthmatic patients using benralizumab.
BR112016008082A2 (en) * 2013-10-15 2017-10-17 Medimmune Llc Methods for treating chronic obstructive pulmonary disease using benralizumab

Also Published As

Publication number Publication date
TW202110479A (en) 2021-03-16
CN114007641A (en) 2022-02-01
AU2020273681A1 (en) 2022-01-06
WO2020230097A1 (en) 2020-11-19
JP2022532220A (en) 2022-07-13
IL287998A (en) 2022-01-01
US20200362027A1 (en) 2020-11-19
EP3969048A1 (en) 2022-03-23
KR20220009967A (en) 2022-01-25
CA3138997A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
HK1245010A1 (en) Genetically modified cells, tissues, and organs for treating disease
IL277190A (en) Methods for treating hpv-associated diseases
IL288677A (en) Methods of treating fabry disease in patients having renal impairment
IL307979A (en) Nanofiber-hydrogel composites for enhanced soft tissue replacement and regeneration
EP3512539A4 (en) Methods for treating pulmonary disease using inter-alpha inhibitor proteins
IL290920A (en) Methods and compositions for treating a disease or disorder
IL288958A (en) Exosomes for disease treatment
IL269083A (en) Methods for preventing and treating heart disease
EP3318275A4 (en) Novel therapeutic agent for pulmonary disease and/or method for screening same
IL285197A (en) Methods and compositions for treating sleep apnea
MX2019013468A (en) Methods for treating chronic obstructive pulmonary disease using benralizumab.
IL276284A (en) Methods for treating farber disease
IL290770A (en) Compounds and methods for treating oxalate-related diseases
PL2717887T3 (en) Methods for treating or preventing graft versus host disease
IL289309A (en) Methods and materials for treating huntington’s disease
EP3768386A4 (en) Gene therapeutics for treating bone disorders
SG11202002088TA (en) Methods and compositions for treating chronic lung diseases
EP3687456A4 (en) Methods for treating degenerative disc disease and chronic lower back pain
HK1249402A1 (en) Methods and compositions for treating muscle disease and disorders
IL287998A (en) Methods for treating chronic obstructive pulmonary disease in an enhanced patient population using benralizumab
EP4051379A4 (en) Therapeutic approach for treating inflammatory bowel disease
MX2018011025A (en) Methods of treating or preventing graft versus host disease.
EP3781262A4 (en) Compositions and methods for treating cardiovascular disease in selected patients
EP3887514A4 (en) Therapeutic gene editing for elane-associated disease
EP3801559A4 (en) Method of reducing pulmonary exacerbations in respiratory disease patients